AR071375A1 - Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto - Google Patents

Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto

Info

Publication number
AR071375A1
AR071375A1 ARP090101363A ARP090101363A AR071375A1 AR 071375 A1 AR071375 A1 AR 071375A1 AR P090101363 A ARP090101363 A AR P090101363A AR P090101363 A ARP090101363 A AR P090101363A AR 071375 A1 AR071375 A1 AR 071375A1
Authority
AR
Argentina
Prior art keywords
active pharmaceutical
permeability
acid
pharmaceutical ingredient
carbonyl
Prior art date
Application number
ARP090101363A
Other languages
English (en)
Inventor
Jan Peter Moeschwitzer
Aldo Vincent Ket
Heike Dinter-Heidorn
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of AR071375A1 publication Critical patent/AR071375A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Abstract

Reivindicacion 1: Una composicion solida termoestable caracterizada porque comprende al menos una sustancia mejoradora de permeabilidad incorporada en una matriz soluble en agua, en donde la suma de la cantidad de dicha sustancia mejoradora de permeabilidad o mezcla de sustancias mejoradoras de permeabilidad y dicha matriz soluble en agua es de al menos 80% p/p de la sustancia seca total, con la condicion de que dicha composicion solida termoestable no contenga un ingrediente farmacéutico activo. Reivindicacion 4: Una composicion farmacéutica que comprende al menos dos fases diferentes, caracterizada porque la primera fase a) comprende un ingrediente farmacéutico activo formulado en un polvo, gránulos, pellas, microesferas o una tableta; y la segunda fase b) comprende una composicion solida termoestable de acuerdo con cualquiera de las reivindicaciones 1-3, y en donde dicho ingrediente farmacéutico activo es una sustancia soluble en agua de permeabilidad deficiente (compuesto BCS III). Reivindicacion 16: Una composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones 4-7, caracterizado porque dicho ingrediente farmacéutico activo se selecciona del grupo que consiste de ácido (3S)-3-[[[1-[2-(2S)-carboxi- 4-[[3-(dimetilamino)propil]metilamino]-4-oxobutil]ciclopentil]carbonil]amino]-2,3,4,5-tetrahidro-2-oxo-1H-1-benzazepina-1-acético, ácido 4-[2-[[[(2S)-1 -[(4'-fluoro[1,1'-bifenil]-4-il)sulfonil]-2,3-dihidro-1H-indol-2-il]carbonil]amino]etoxi]-benzoico y ácido 4-[[[[(2S)-2,3-dihidro-1-[[2',4'-difluoro[1,1'-bifenil]-4-il]sulfonil]-1H-indol-2-il]carbonil]amino]metil]bencenoacético.
ARP090101363A 2008-04-22 2009-04-17 Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto AR071375A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08103657 2008-04-22

Publications (1)

Publication Number Publication Date
AR071375A1 true AR071375A1 (es) 2010-06-16

Family

ID=39816874

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101363A AR071375A1 (es) 2008-04-22 2009-04-17 Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto

Country Status (18)

Country Link
US (1) US20090263479A1 (es)
EP (1) EP2268270A2 (es)
JP (1) JP5726067B2 (es)
KR (1) KR20110005883A (es)
CN (1) CN102119025B (es)
AR (1) AR071375A1 (es)
AU (1) AU2009240050A1 (es)
BR (1) BRPI0910758A2 (es)
CA (1) CA2720658C (es)
CO (1) CO6300932A2 (es)
DO (1) DOP2010000318A (es)
EA (1) EA032766B1 (es)
EC (1) ECSP10010514A (es)
IL (1) IL208370A0 (es)
MX (1) MX2010011564A (es)
NZ (1) NZ588369A (es)
TW (1) TW200948399A (es)
WO (1) WO2009130204A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
CN104661652B (zh) 2012-09-27 2018-08-28 巴斯夫欧洲公司 包含至少一种水溶性维生素e衍生物和至少一种亲水聚合物的储存稳定的无粉尘均质颗粒状配制剂
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
EP2911651B1 (en) 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
PL2953617T3 (pl) * 2013-02-06 2020-05-18 Hermes Arzneimittel Gmbh Kompozycje farmaceutyczne zawierające leki w małej dawce
BR112016024421A2 (pt) * 2014-06-18 2017-08-15 Chugai Pharmaceutical Co Ltd composição farmacêutica, cápsula e uso da composição farmacêutica
HUE051900T2 (hu) 2014-06-20 2021-03-29 Hermes Arzneimittel Gmbh Íz-leplezett orális gyógyászati készítmény
CN111053755B (zh) * 2019-12-31 2022-03-29 金日制药（中国）有限公司 一种高渗透性的头孢克肟胶囊制剂制备方法
US20230172866A1 (en) * 2020-03-18 2023-06-08 Sichuan Haisco Pharmaceutical Co., Ltd. Oral pharmaceutical composition
CN112704649A (zh) * 2020-12-30 2021-04-27 广东臻香荟生物科技有限公司 一种具备抑菌性能的香薰液
JP7368548B2 (ja) 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN114601800B (zh) * 2021-09-28 2023-07-28 天津瑞普生物技术股份有限公司 一种甲磷丙泊酚钠无菌粉针剂及其制备方法
WO2023168089A2 (en) * 2022-03-04 2023-09-07 Abitec Corporation Tablet dosage forms for lipid-based drug delivery systems
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US3477864A (en) * 1965-05-07 1969-11-11 Sumitomo Chemical Co Process for coating pharmaceutical preparations with a hydroxy propyl methyl cellulose-sealing agent moisture-preventing film
US3692543A (en) * 1971-01-28 1972-09-19 Wellman Lord Inc Food products
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
JPH085086B2 (ja) * 1992-07-14 1996-01-24 メリート株式会社 金型装置
DE19709532A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
DK1476138T3 (da) * 2002-02-21 2012-02-20 Valeant Internat Barbados Srl Formuleringer med modificeret frigivelse af mindst én form af tramadol
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
US7262184B2 (en) * 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
EP1677770A2 (en) * 2003-10-31 2006-07-12 Dexcel Ltd. Stable lansoprazole formulation
WO2006036614A2 (en) 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
US20060240108A1 (en) * 2005-04-26 2006-10-26 Bernard Bobby L Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
AU2007212197B2 (en) * 2006-02-09 2012-12-13 Merck Sharp & Dohme Corp. Polymer formulations of CETP inhibitors
CA2654566A1 (en) 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
KR101434334B1 (ko) * 2006-10-20 2014-08-28 아비에 비.브이. 화학 물질의 마이셀 나노입자
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto

Also Published As

Publication number Publication date
EA201071218A1 (ru) 2011-06-30
US20090263479A1 (en) 2009-10-22
JP2011518208A (ja) 2011-06-23
IL208370A0 (en) 2010-12-30
NZ588369A (en) 2012-06-29
CN102119025B (zh) 2014-09-03
KR20110005883A (ko) 2011-01-19
MX2010011564A (es) 2011-03-02
EA032766B1 (ru) 2019-07-31
CN102119025A (zh) 2011-07-06
JP5726067B2 (ja) 2015-05-27
CA2720658C (en) 2016-07-12
AU2009240050A1 (en) 2009-10-29
WO2009130204A2 (en) 2009-10-29
BRPI0910758A2 (pt) 2018-03-20
DOP2010000318A (es) 2011-01-15
EP2268270A2 (en) 2011-01-05
ECSP10010514A (es) 2010-11-30
WO2009130204A3 (en) 2010-08-05
CO6300932A2 (es) 2011-07-21
TW200948399A (en) 2009-12-01
CA2720658A1 (en) 2009-10-29

Similar Documents

Publication Publication Date Title
AR071375A1 (es) Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
WO2010072958A3 (fr) Composition pharmaceutique topique comprenant un principe actif sensible a l'eau
BRPI0508540A8 (pt) Composto, composição farmacêutica, e, uso de um composto
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
HK1096034A1 (en) A solid dosage form comprising a fibrate
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
HRP20230753T3 (hr) Farmaceutski pripravci koji sadrže nilotinib
TNSN08475A1 (en) Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same
HRP20120948T1 (hr) Derivati piridina koji su korisni kao aktivatori glukokinaze
WO2008065097A3 (en) Stabilized solid pharmaceutical composition of candesartan cilexetil
IL188980A0 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
EA201071409A1 (ru) Новые соли (4-{[(5-{[(3-хлорфенил)метил]окси}-2-метилфенил)карбонил]амино}-3-метилфенил)уксусной кислоты
WO2011020928A3 (en) Photoresponsive sunscreen composition
WO2006060681A3 (en) Pharmaceutical composition containing an anti-nucleating agent
CA2494473A1 (en) Stabilized protein compositions for topical administration and methods of making same
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
RU2015139983A (ru) СОСТАВ С АМОРФНЫМ L-5-МЕТИЛТЕТРАГИДРОФОЛАТОМ КАЛЬЦИЯ (L-5-MTГФ-Cа)
ES2337848T3 (es) Formulaciones de valsartan.
HRP20100216T1 (hr) Kruti farmaceutski pripravak koji sadrži irbesartan
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
WO2011056775A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин

Legal Events

Date Code Title Description
FA Abandonment or withdrawal